The p21 cyclin–dependent kinase inhibitor suppresses tumorigenicity in vivo

Nature Medicine

Volumn 1, Issue 10, 1995, Pages 1052-1056

  Yang, Zhi Yong ^a   Perkins, Neil D ^a   Ohno, Takeshi ^a   Nabel, Gary J ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; ENZYME INHIBITOR; PROTEIN P21;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER INHIBITION; GENE TRANSFER; HUMAN; HUMAN CELL; MELANOMA; MITOSIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

3T3 CELLS; ANIMAL; CELL CYCLE; CELL DIFFERENTIATION; CELL DIVISION; CYCLIN-DEPENDENT KINASES; CYCLINS; GENE TRANSFER TECHNIQUES; GENES, TUMOR SUPPRESSOR; GROWTH INHIBITORS; HUMAN; MELANOMA; MICE; MICE, INBRED BALB C; MICE, NUDE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR CELLS, CULTURED;

EID: 0028820762     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1095-1052     Document Type: Article

References (44)

1. King, R.W., Jackson, P.K. & Kirschner, M.W. Mitosis in transition. Cell 79, 563-571 (1994).
2. Heichman, K.A. & Roberts, J.M. Rules to replicate by. Cell 79, 557-562 (1994).
3. Sherr, C.J. G1 phase progression: Cycling on cue. Cell 79, 551-555 (1994)
4. Nurse, P. Ordering S phase and M phase in the cell cycle. Cell 79, 547-550 (1994).
5. Hunter, T. & Pines, J. Cyclins and cancer II: Cyclin D and CDK inhibitors come of age. Cell 79, 573-582 (1994).
6. Peter, M. & Herskowitz, I. Joining the complex: cyclin-dependent kinase inhibitory proteins and the cell cycle. Cell 79, 181-184 (1994).
7. Chang, F. & Herskowitz, I. Identification of a gene necessary for cell cycle arrest by a negative growth factor of yeast: FAR1 is an inhibitor of a G1 cyclin, CLN2. Cell 63, 999-1011 (1990).
8. Zhang, H., Hannon, GJ. & Beach, D. p21-containing cyclin kinases exist in both active and inactive states. Genes Dev. 8, 1750-1758 (1994).
9. Xiong, Y. et al. p21 is a universal inhibitor of cyclin kinases. Nature 366, 701-704 (1993).
10. Harper, J.W., Adami, G.R., Wei, N., Keyomarsi, K. & Elledge, S.J. The p21 Cdk-interacting protein Cipl is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75, 805-816 (1993).
11. Kipl, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78, 59-66 (1994).
12. Toyoshima, H. & Hunter, T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78, 67-74 (1994).
13. Serrano, M., Hannon, G.J. & Beach, D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366, 704-707 (1993).
14. INK4B is a potential effector of TGF-induced cell cycle arrest. Nature 371, 257-261 (1994).
15. el-Deiry, W.S. et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825 (1993).
16. Noda, A., Ning, Y., Venable, S.F., Pereira-Smith, O.M. & Smith, J.R. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Expl. Cell Res. 211, 90-98 (1994).
17. Gu, Y., Turck, C.W. & Morgan, D.O. Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 366, 707-710 (1993).
18. Li, Y., Jenkins, C.W., Nichols, M.A. & Xiong, Y. Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene 9, 2261-2268(1994).
19. el-Deiry, W.S. et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apop-tosis. Cancer Res. 54, 1169-1174 (1994).
20. 1 arrest and long-term induction of Cipl in normal human fibroblasts. Genes Dev. 8, 2540-2551 (1994).
21. Dulic, V. et al. p5 3-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76, 1013-1023 (1994).
22. Li, R., Waga, S., Hannon, G.J., Beach, D. & Stillman, B. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 371, 534-537(1994).
23. Li, C.Y., Suardet, L. & Little, J.B. Potential role of WAFl/Cipl/p21 as a mediator of TGF-beta cytoinhibitory effect. J. biol. Chem. 270, 4971-4974 (1995).
24. Symonds, H. et al. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78, 703-711 (1994).
25. Chen, P.L., Scully, P., Shew, J.Y., Wang, J.Y. & Lee, W.H. Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell 58, 1193-1198 (1989).
26. Kato, J.T., Matsushiml, H., Hiebert, S.W., Ewen, M.E. & Sherr, C.J. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev. 7, 331-342 (1993).
27. Hu, Q.J., Lees, J.A., Buchleovich, K.J. & Harlow, E. The retinoblastoma protein physically associates with the human cdc2 kinase. Molec. cell. Biol. 12, 971-980 (1992).
28. Lin, B.T.-Y., Gruenwald, S., Morla, A.O., Lee, W.-H. & Wang, J. Retinoblastoma cancer suppressor gene product is a substrate of the cell cycle regulator cdc2 kinase. EMBO. 10, 857-866 (1991).
29. Ewen, M.E. et al. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 73, 487-497 (1993).
30. Riley, D.J., Lee, E.Y. & Lee, W.H. The retinoblastoma protein, more than a tumor suppressor. Annu. Rev. Cell Biol. 10, 1-29 (1994).
31. Chellappen, S.P., Heibert, S., Mudryi, M., Horowitz, J.M. & Nevins, J.R. The E2F transcription factor is a cellular target for the Rb protein. Cell 65, 1053-1061 (1991).
32. Dynlacht, B.D., Flores, O., Lees, J.A. & Harlow, E. Differential regulation of E2F transactivation by cyclin/CDK2 complexes. Genes Dev. 8, 1722-1786 (1994).
33. Schneider, K.R., Smith, R.L. & O’Shea, E.K. Phosphate-regulated inactivation of the kinase PH080-PH085 by the CDK inhibitor PH081. Science 266, 122-126 (1994).
34. Kaffman, A., Herskowitz, I., Tjian, R. & O’Shea, E.K. Phosphorylation of the transcription factor PH04 by a cyclin-CDK complex, PH080-PH085. Science 263, 1153-1156(1994).
35. Christman, J.K., Mendelsohn, N., Herzog, D. & Schneiderman, N. Effect of 5-azacytidine on differentation and DNA methylation in human promyelocytic leukemia cells (HL-60). Cancer Res. 43, 763-769 (1983).
36. Samid, D., Shack, S. & Sherman, L.T. Phenylacetate: A novel nontoxic inducer of tumor cell differentation. Cancer Res. 52, 1988-1992 (1992).
37. Pierce, G.B. & Speers, W.C. Tumor as caricatures of the process of tissue renewal: Prospects for therapy by directing differentation. Cancer Res. 48, 1996-2006 (1988).
38. Leftwich, J.A. & Hall, R.E. Enhancement of phorbol ester-induced HL-60-medi-ated cytotoxicity by retinoic acid, dimethyl sulfoxide and 5-azacytidine. Cancer Res. 46, 3789-3792 (1986).
39. Chen, S.H. et al. Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc. natn. Acad. Sci. U.S.A. 92, 2577-2581 (1995).
40. Davidson, B.L., Allen, E.D., Kozarsky, K.F., Wilson, J.M. & Roessler, BJ. A model system for in vivo gene transfer into the central nervous system using an adenoviral vector. Nature Genet 3, 219-223 (1993).
41. Ohno, T. et al. Gene therapy for vascular smooth muscle cell proliferation following arterial injury. Science 265, 781-784 (1994).
42. Mosman, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. immunol. Methods 65, 55-63 (1983).
43. Ito, S., Wakamatsu, K. & Ozeki, H. Spectrophotometric assay of eumelanins in tissue samples. Anal. Biochem. 215, 273-277 (1993).
44. Gorczyca, W. et al. Induction of DNA strand breaks associated with apoptosis during treatment of leukemias. Leukemia 7, 659-670 (1993).